Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Akari Therapeutics PLC AKTX

Healthcare Biotechnology
Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric... see more

Recent & Breaking News (NDAQ:AKTX)

IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Akari Therapeutics, Plc and Advises Investors With Losses to Contact the Firm

Business Wire May 15, 2017

SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Akari Therapeutics, Plc (Nasdaq: AKTX) To Contact Brower Piven Before The Lead Plaintiff Deadline

GlobeNewswire May 15, 2017

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Akari Therapeutics, Plc and Encourages Investors with Losses to Contact the Firm

Business Wire May 15, 2017

The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Akari Therapeutics, Plc Investors and Encourages Investors to Contact the Firm

Business Wire May 15, 2017

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Akari Therapeutics, Plc and Encourages Investors with Losses to Contact the Firm

Business Wire May 15, 2017

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Akari Therapeutics, Plc - AKTX

Business Wire May 15, 2017

Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Akari Therapeutics, Plc

GlobeNewswire May 15, 2017

INVESTOR ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Akari Therapeutics, Plc

Business Wire May 15, 2017

AKARI THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akari Therapeutics, Plc – (AKTX)

GlobeNewswire May 14, 2017

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Akari Therapeutics, Plc and Encourages Investors with Losses to Contact the Firm

Business Wire May 13, 2017

AKARI LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Akari Therapeutics, Plc To Contact The Firm

GlobeNewswire May 12, 2017

IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Akari Therapeutics, Plc and Encourages Investors With Losses to Contact the Firm

Business Wire May 12, 2017

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Akari Therapeutics Plc (AKTX)

PR Newswire May 12, 2017

SHAREHOLDER ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Akari Therapeutics, Plc

Business Wire May 12, 2017

Glancy Prongay & Murray LLP Files Securities Class Action Lawsuit Against Akari Therapeutics, Plc

Business Wire May 12, 2017

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Akari Therapeutics, Plc and Advises Investors with Losses to Contact the Firm

Business Wire May 12, 2017

AKARI INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Akari Therapeutics, Plc To Contact The Firm

PR Newswire May 12, 2017

INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Akari Therapeutics, Plc

Business Wire May 12, 2017

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Hertz Global Holdings, Inc. - HTZ

PR Newswire May 12, 2017

Glancy Prongay & Murray LLP Commences Investigation on Behalf of Akari Therapeutics, Plc Investors

Business Wire May 12, 2017